Efficacies and Chemical Structures of Modern Drugs for Hepatitis C Virus Treatment


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Hepatitis C virus (HCV) is the leading cause of chronic liver disease, surpassing hepatitis B virus and alcohol. The paradigm for treating HCV has radically changed over the last 20 years. The tolerability and duration of treating HCV patients was altered fundamentally by the emergence of modern and more efficacious treatment regimens and plans. Nevertheless, the risk of developing serious adverse reactions, including those due to drug–drug interactions, remains high. Currently, eight drugs are approved for treating HCV and avoid the use of interferons. The present article reviews these drugs with respect to their efficacy and safety for use in patients with various HCV genotypes.

作者简介

A. Kazakov

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

编辑信件的主要联系方式.
Email: a.kazakov15@gmail.com
俄罗斯联邦, 8/2 Petrovskii Blvd, Moscow, 127051

V. Lepakhin

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Email: a.kazakov15@gmail.com
俄罗斯联邦, 8/2 Petrovskii Blvd, Moscow, 127051

T. Bukatina

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Email: a.kazakov15@gmail.com
俄罗斯联邦, 8/2 Petrovskii Blvd, Moscow, 127051

I. Snegireva

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Email: a.kazakov15@gmail.com
俄罗斯联邦, 8/2 Petrovskii Blvd, Moscow, 127051

K. Zatolochina

Peoples Friendship University of Russia

Email: a.kazakov15@gmail.com
俄罗斯联邦, Moscow, 117198


版权所有 © Springer Science+Business Media, LLC, part of Springer Nature, 2018
##common.cookie##